Synaptixbio
Synaptixbio is a startup headquartered in Oxford, United Kingdom, founded in 2021. It has won about £2.50m in competitive Innovate UK grants since 2023, according to UK Research and Innovation.
Part of the 311 Institute Global Startups Directory (311institute.com). Last updated .
Innovation grants
Synaptixbio has won about £2.50m in competitive Innovate UK grants since 2023.
- SynaptixBio: A demonstration of antisense oligonucleotide therapeutics for the treatment of a rare paediatric TUBB4A-related leukodystrophy - A first-in-human clinical trial (£2.00m, 2024)
- SynaptixBio: Development of antisense oligonucleotide therapeutics for the treatment of rare paediatric TUBB4A-related leukodystrophies (£499k, 2023)
R&D ecosystem
Synaptixbio sits inside the London and the Golden Triangle R&D ecosystem in the Global R&D Labs Directory.
Other startups in Oxford
Related
- Innovation profile of Oxford
- United Kingdom: economy and key statistics
- Global Investors Directory
- All 311 Indexes
Questions and answers
What does Synaptixbio do?
Synaptixbio works in biotechnology. Its Innovate UK projects include: SynaptixBio: A demonstration of antisense oligonucleotide therapeutics for the treatment of a rare paediatric TUBB4A-related leukodystrophy - A first-in-human clinical trial.
Where is Synaptixbio based?
Synaptixbio is headquartered in Oxford, United Kingdom.
When was Synaptixbio founded?
Synaptixbio was founded in 2021.
Source records: Companies House and UK Research and Innovation.
© 311 Institute 2026. Facts from the official sources linked on this page. The selection, classification and links are the proprietary work of the 311 Institute, protected by copyright and database rights.